After the first ancient studies on microbial slime (the name by which the biofilm matrix was
initially indicated), multitudes of studies on the morphology, composition and physiology of …

Antibiotic treatment failure is of growing concern. Genetically encoded resistance is key in
driving this process. However, there is increasing evidence that bacterial antibiotic …

Pseudomonas aeruginosa is a leading cause of chronic respiratory infections in people with
cystic fibrosis (CF), bronchiectasis or chronic obstructive pulmonary disease (COPD), and …

Bacterial infections of the cornea, or bacterial keratitis (BK), are notorious for causing rapidly
fulminant disease and permanent vision loss, even among treated patients. In the last sixty …

Bacteria can be genetically engineered to act as therapeutic delivery vehicles in the
treatment of tumors, killing cancer cells or activating the immune system. This is known as …

The management of antibiotic-resistant, bacterial biofilm infections in chronic skin wounds is
an increasing clinical challenge. Despite advances in diagnosis, many patients do not …

Pseudomonas aeruginosa (PA) is a highly, if not the most, versatile microorganism capable
of colonizing diverse environments. One of the niches in which PA is able to thrive is the …

In recent years considerable improvements have been made in increasing the life
expectancy of patients with cystic fibrosis. New highly effective modulator therapies targeting …

Chronic pulmonary infection caused by Pseudomonas aeruginosa (P. aeruginosa) is a
common lung disease with high mortality, posing severe threats to public health. Highly …

Novel therapeutics designed to target the polymeric matrix of biofilms requires innovative
techniques to accurately assess their efficacy. Here, multiple particle tracking (MPT) was …